Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for rivaroxaban tablets, allowing the product to be marketed [1] Group 1 - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - The drug is also indicated for the treatment and prevention of deep vein thrombosis (DVT) [1] - Additionally, it is used for the treatment of pulmonary embolism (PE) and for the prevention of venous thromboembolism (VTE) in acutely ill patients [1]

Core Insights - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, has received FDA approval for the abbreviated new drug application (ANDA) for Doxycycline capsules, which are primarily used for treating inflammatory lesions (papules and pustules) of rosacea in adult patients [1] Financial Summary - As of the announcement date, Changzhou Pharmaceutical Factory has invested approximately RMB 10.83 million in research and development for Doxycycline capsules [1] - The projected sales revenue for Doxycycline capsules in the U.S. for 2024 is approximately $130 million [1]

格隆汇10月14日丨上海医药(601607.SH)公布，公司下属常州制药厂有限公司(称"常州制药厂")收到美国 食品药品监督管理局(称"美国FDA")的通知，其关于多西环素胶囊(基本情况详阅正文，称"该药品")的 简略新药申请("ANDA"，即美国仿制药申请)已获得批准，多西环素胶囊(40mg)，内含两种类型的多西 环素微丸(30mg速释微丸和10mg迟释微丸),主要用于成人患者的玫瑰痤疮(红斑痤疮)的炎症性病变(丘疹 和脓疱)。 ...

Core Insights - Shanghai is leading the nation in the innovation of pharmaceuticals and medical devices, with 30 approved domestic Class I innovative drugs from 2021 to September 2025, accounting for 17% of the national total [1] - The biopharmaceutical industry in Shanghai reached a scale of 500.57 billion yuan in the first half of this year, with expectations to surpass 1 trillion yuan for the full year [2] - Shanghai's License-out transactions for innovative drugs reached 38 in 2024, representing 35% of the national total, with a transaction value of 30.7 billion USD, accounting for 47% of the national total [3] Industry Growth - The biopharmaceutical industry in Shanghai has shown consistent growth, increasing from 761.71 billion yuan in 2021 to an estimated 984.70 billion yuan in 2024, with a compound annual growth rate of 8.94% [2] - By the end of 2024, Shanghai is expected to have 2,183 biopharmaceutical enterprises, covering manufacturing, services, and wholesale [2] - Shanghai has seen 46 companies go public from 2021 to 2024, with 4 new listings in 2023 alone [2] International Recognition - Since 2021, 9 drugs have been approved in international markets such as the US and Japan, indicating the global recognition of Shanghai's innovative capabilities [3] - Major international pharmaceutical and medical device companies have established headquarters or R&D centers in Shanghai, with 19 out of the top 20 in each category present [2] Policy Support - Shanghai has implemented various policies to support the biopharmaceutical industry, including regulations and action plans focused on synthetic biology, cell and gene therapy, and AI in medicine [4] - A biopharmaceutical industry mother fund with a total scale of 22.5 billion yuan has been established, along with a 10 billion yuan merger fund targeting strategic acquisitions in traditional Chinese medicine, vaccines, and high-end medical devices [4] - From 2021 to 2024, Shanghai's biopharmaceutical sector has secured 238.37 billion yuan in financing, ranking among the top in the country [4] Innovation Ecosystem - Shanghai has built a comprehensive innovation ecosystem that spans from research to clinical application, providing new momentum for high-quality development in the biopharmaceutical industry [5]

Core Insights - The eighth Pujiang Pharmaceutical Health Industry Innovation Development Summit was held with the theme "Open Source Innovation · Collaborative Chain Symbiosis" [1] - The summit serves as a flagship event of the "Shanghai Biopharmaceutical Industry Week" and has become a leading platform for innovation in China's pharmaceutical and health industry [1] - The event gathered over 300 influential guests from government, industry, academia, research, and investment sectors to discuss the future of the pharmaceutical health industry [1] Industry Overview - The summit showcased the latest trends and insights in the pharmaceutical industry, emphasizing Shanghai's strategic position as a global biopharmaceutical innovation hub [1] - The event highlighted the importance of integrating the entire industry chain, innovation chain, and capital chain to accelerate the global reach of Chinese innovative drugs [1] Company Initiatives - Shanghai Pharmaceuticals, as a core platform of the Shanghai Shendi Group's life and health industry, is playing a "chain leader" role in promoting the construction of the Shanghai Frontier Innovation Center [2] - The company has implemented a "one table" mechanism to consolidate resources from government, industry, academia, research, and investment, attracting multiple multinational pharmaceutical companies and national-level institutions [2] - Shanghai Pharmaceuticals aims to assist Shanghai in building a world-class biopharmaceutical industry cluster [2]

作为上海生物医药产业的"链主"企业，上海医药已经连续6年入选了财富世界500强榜单，2024年实现了营业收入2752.51亿元，跑出了发展加速 度。 在上海医药执行董事、总裁沈波看来，生物医药全链条创新突破，将成为行业的发展主线。加强前沿领域源头创新和关键核心技术的攻关，抢占 产业发展的制高点，强化产业链的自主可控，将成为未来发展的重要方向。 生物医药创新如何更快落地？产业如何更强链接？资本如何更好赋能？记者从10月11日召开的第八届浦江医药健康产融创新发展峰会（以下简称 浦江峰会）上获悉，上海将持续加大政策供给，汇聚各方力量，全力推动基础研究、孵化转化、临床试验、审评、审批落地生产推广应用的全链 条加速，加快建设世界级生物医药创新高地和产业集群。 作为上海国际生物医药产业周的重要组成部分，浦江峰会已成为引领中国医药健康产业发展的创新风向标，亦是汇聚全球智慧、促进产学研深度 融合的高端学术平台。 本届峰会由上实集团、中国医药企业管理协会指导，上海医药主办，上海前沿承办，汇聚了来自政、产、学、研、资的300余位参会嘉宾，线上参 与人数超万人，共绘医药健康产业的未来蓝图。 上海市科委副主任黄红介绍，生物医药产业是 ...

Core Insights - The 8th Pujiang Pharmaceutical Health Industry Innovation Development Summit was held in Shanghai, focusing on "Open Source Innovation and Collaborative Chain Symbiosis" [1] - The summit has become a leading platform for the development of China's pharmaceutical and health industry, gathering over 300 influential guests from various sectors [1][2] Policy and Authority - Key figures including the President of Shanghai Pharmaceuticals and representatives from the Shanghai Municipal Government and the National Health Commission emphasized the importance of technological innovation in reshaping health care [2] - The summit aligns with national strategies to foster a collaborative platform that integrates technology and health sectors, promoting a biopharmaceutical innovation ecosystem [2][3] Industry Trends and Discussions - The summit covered critical aspects of the pharmaceutical health industry, including policy, scientific advancements, and capital market trends [3] - Experts discussed the collaborative management of health technology innovation, the support system for innovative drugs, and the lifecycle value management of pharmaceuticals [3] - Representatives from international financial institutions shared insights on global biopharmaceutical investment trends and IPO developments [3] Cross-Disciplinary Collaboration - The summit featured a special segment called "Pujiang Exchange: Frontline Discussion," where leaders from various sectors engaged in dialogues about "Science Leading Unbounded Innovation" [4] - This platform facilitated networking and the exchange of innovative ideas, fostering high-quality collaborations for future projects [4] Strategic Development - The Pujiang Summit has evolved into a significant indicator of innovation in China's pharmaceutical health industry, showcasing Shanghai's strategic position as a global biopharmaceutical innovation hub [6] - Shanghai Pharmaceuticals aims to enhance its role as a "chain leader" in the innovation center, attracting multinational pharmaceutical companies and national institutions [6]

Core Insights - The pharmaceutical commercial sector saw a slight increase of 0.17% on October 10, with Guofa Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Guofa Co., Ltd. (600538) closed at 5.85, up 4.28% with a trading volume of 178,800 shares and a transaction value of 103 million yuan [1] - Other notable gainers included Dajia Weikang (301126) up 1.89%, Yingte Group (000411) up 1.77%, and Liuyao Group (603368) up 1.75% [1] - Conversely, the sector also experienced declines, with Saily Medical (603716) down 4.51% and Jianfa Zhixin (301584) down 4.01% [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 161 million yuan from institutional investors, while retail investors saw a net inflow of 214 million yuan [2] - The data indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 27.32 million yuan from institutional investors, while it faced a net outflow of 32.58 million yuan from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 4.95 million yuan from institutional investors, but also faced outflows from speculative funds [3] - Guofa Co., Ltd. (600538) had a net inflow of 4.07 million yuan from institutional investors, indicating some level of interest despite the overall outflow trend [3]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 编号：临2025-089 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三 個行權期 2025 年第三季度自主行權結果公告》僅供參閱。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...